Phase 1 Open-label Two-stage Safety and Tolerability Study With Subcutaneous Administration of Andes-1537 for Injection in Patients With Specific Types of Advanced Solid Tumors That Are Refractory To or No Available Standard Therapy
Latest Information Update: 25 Feb 2022
At a glance
- Drugs Andes 1537 (Primary)
- Indications Adenocarcinoma; Biliary cancer; Cervical cancer; Gallbladder cancer; Gastric cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Andes Biotechnologies
Most Recent Events
- 23 Feb 2022 Status changed from active, no longer recruiting to completed.
- 09 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 09 Dec 2021 Planned End Date changed from 1 Nov 2022 to 1 Apr 2022.